Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

METHODS AND COMPOSITIONS FOR DIRECT LINEAGE REPROGRAMMING OF ASTROCYTES TO OLIGODENDROCYTE LINEAGE CELLS

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Publication Date:
    December 26, 2024
  • Additional Information
    • Document Number:
      20240424140
    • Appl. No:
      18/642049
    • Application Filed:
      April 22, 2024
    • Abstract:
      The present application provides methods for production of induced oligodendrocyte lineage cells (IOLCs) from donor astrocytes comprising contact the donor astrocytes with a polynucleotide comprising a nucleic acid encoding a single transcription factor (TF), wherein the single TF is Olig2, Sox10, or Nkx6.2. Also provided are pharmaceutical compositions for performing the method and associated uses thereof.
    • Claim:
      1. An in vivo method for production of induced oligodendrocyte lineage cells (iOLCs) from donor astrocytes comprising contacting the donor astrocytes with a polynucleotide comprising a nucleic acid encoding a single transcription factor (TF), wherein the single TF is Olig2, Sox10, or Nkx6.2, wherein the nucleic acid encoding the single TF is operably linked to an astrocyte-specific promoter sequence.
    • Claim:
      2. The method of claim 1, wherein the donor astrocytes are GFAP+cortical astrocytes.
    • Claim:
      3. The method of claim 1, wherein the polynucleotide is within a vector, which is a viral vector, such as an adenoviral vector, an adeno-associated viral vector or a lentiviral vector, or a non-viral vector.
    • Claim:
      4. The method of claim 1, wherein the polynucleotide is packaged in a nanoparticle, such as a lipid nanoparticle.
    • Claim:
      5. The method of claim 1, wherein the single TF is Olig2 and the iOLCs are induced oligodendrocyte progenitor cells.
    • Claim:
      6. The method of claim 1, wherein the single TF is Sox10 and the iOLCs are myelinating olidodendrocytes and/or pre-myelinating oligodendrocyte precursor cells.
    • Claim:
      7. The method of claim 1, wherein the single TF is is Nkx6.2 and the iOLCs are myelinating olidodendrocytes.
    • Claim:
      8. A vector comprising a nucleic acid encoding a single transcription factor (TF), wherein the single TF is Olig2, Sox10, or Nkx6.2, and wherein the nucleic acid encoding the single TF is operably linked to an astrocyte-specific promoter sequence.
    • Claim:
      9. The vector of claim 8, wherein the vector is a viral vector, such as an adenoviral vector, an adeno-associated viral vector or a lentiviral vector.
    • Claim:
      10. The vector of claim 8, wherein the astrocyte-specific promoter sequence is a glial fibrillary acidic protein (GFAP) promoter.
    • Claim:
      11. A viral particle comprising the vector of claim 8.
    • Claim:
      12. A host cell comprising the vector of claim 8.
    • Claim:
      13. A pharmaceutical composition comprising a nucleic acid encoding a single transcription factor (TF), wherein the single TF is Olig2, Sox10, or Nkx6.2, and wherein the nucleic acid encoding the single TF is operably linked to an astrocyte-specific promoter sequence and a pharmaceutically acceptable carrier or excipient.
    • Claim:
      14. The pharmaceutical composition of claim 13, wherein the nucleic acid is in a viral vector, a non-viral vector or a viral particle.
    • Claim:
      15. A method for prevention or treatment of a disease or disorder that affects astrocyte and/or oligodendrocyte lineage cells in a subject, said method comprising administering to the subject a nucleic acid for expression of a single transcription factor (TF), wherein the single TF is Olig2, Sox10, or Nkx6.2, in astrocytes within the subject.
    • Claim:
      16. The method according to claim 15, wherein the disease or disorder is a myelin-related disease or disorder.
    • Claim:
      17. The method of claim 15, wherein the nucleic acid is in a vector and wherein the nucleic acid encoding the single TF is operably linked to an astrocyte-specific promoter sequence.
    • Claim:
      18. The method of claim 15, wherein the nucleic acid is in a pharmaceutical composition and the method comprises administering the composition to the subject via direct intracranial administration, intracranial injection, intracerebroventricular injection, intracisternal injection, intrathecal injection, intravenous injection, intraperitoneal injection, intraarterial, delivery via nanoparticles, and/or administration using focused ultrasound.
    • Current International Class:
      61; 61; 12
    • Accession Number:
      edspap.20240424140